SINTX Technologies Announces Pricing of $1.5 Million Public Offering of Common Stock

Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
SINTX Technologies, Inc. announces the pricing of a public offering of 71,600,000 shares of common stock at $0.021 per share, expecting gross proceeds of $1.5 million. The offering is set to close on April 5, 2024, with intentions to utilize the net proceeds for working capital and general corporate purposes.
  • None.
  • The offering price of $0.021 per share is significantly lower than the previous market price, potentially diluting existing shareholders' value.

The recent public offering announcement by SINTX Technologies indicates a strategic move to enhance liquidity and support ongoing operations. The offering price at $0.021 per share is substantially lower than typical market prices, which could imply either a dilutive effect for current shareholders or a potential undervaluation of the company's stock. Investors should examine the historical performance of SINTX's stock and compare it with industry benchmarks to understand the potential impact of such a low offering price on market perception.

Furthermore, the expected gross proceeds of approximately $1.5 million, while providing immediate working capital, may not significantly alter the company's financial trajectory unless coupled with a robust strategic plan. Stakeholders should consider the company's long-term growth initiatives and how this capital infusion aligns with those objectives. It is also noteworthy that Maxim Group LLC is acting as the sole placement agent, which could suggest a targeted approach in the placement of shares.

From a financial perspective, the capital raised through this offering is relatively modest for a NASDAQ-listed company. The use of proceeds for 'working capital and general corporate purposes' is quite broad and does not specify any particular growth strategy. This could raise questions about the company's future revenue streams and profitability. Investors should scrutinize SINTX's financial statements and cash flow projections to assess the adequacy of this capital raise in meeting the company's short-term obligations and supporting any planned expansions or R&D efforts.

It is also essential to analyze the terms of the shelf registration statement under which this offering is made. The flexibility of a shelf registration allows for funds to be raised over time, but it can also lead to shareholder dilution if not managed carefully. The timing and size of the offering, as well as market conditions at the time of the sale, will determine the actual impact on the company's stock price and shareholder value.

SALT LAKE CITY, UT, April 03, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, today announced the pricing of its previously announced public offering of 71,600,000 shares of its common stock at a public offering price of $0.021 per share. Gross proceeds from the offering are expected to be approximately $1.5 million before deducting placement agent fees and estimated offering expenses. The offering is expected to close on April 5, 2024, subject to customary closing conditions. SINTX intends to use the net proceeds of the offering, if any, for working capital and general corporate purposes.

Maxim Group LLC is acting as sole placement agent in connection with this offering.

The public offering is being made pursuant to an effective shelf registration statement on Form S-3, as amended (File No. 333-274951), previously filed with the U.S. Securities and Exchange Commission (SEC) on October 12, 2023, as amended, and declared effective on November 27, 2023. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the public offering have been filed with the SEC. A final prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at When available, copies of the final prospectus supplement and accompanying prospectus relating to the public offering may also be obtained by contacting Maxim Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Prospectus Department, or by telephone at (212) 895-3745 or by email at

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About SINTX Technologies, Inc.

SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past two years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. The Company has manufacturing facilities in Utah and Maryland.

For more information on SINTX Technologies or its silicon nitride material platform, please visit

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements, including those relating to the offering, within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things: satisfaction of customary closing conditions related to the offering and sale of the shares of common stock, the use of proceeds from the offering, and SINTX’s ability to complete the offering; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; factors affecting SINTX’s quarterly and annual results; SINTX’s ability to manage its growth; SINTX’s ability to achieve and sustain profitability; demand for SINTX’s products; SINTX’s ability to compete successfully; SINTX’s ability to rapidly develop and introduce new products; SINTX’s ability to develop and execute on successful business strategies; SINTX’s ability to comply with changes and applicable laws and regulations that are applicable to its businesses; SINTX’s ability to safeguard its intellectual property; SINTX’s success in defending legal proceedings brought against it; trends in the medical device industry; and general economic conditions. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations, and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in the Registration Statement and SINTX’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 27, 2024, and in SINTX’s other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

SINTX Technologies


What is the pricing of SINTX Technologies, Inc.'s public offering?

SINTX Technologies, Inc. announced a public offering of 71,600,000 shares of common stock at a price of $0.021 per share.

When is the expected closing date of the public offering?

The public offering is expected to close on April 5, 2024, subject to customary closing conditions.

How much are the gross proceeds from the offering?

The gross proceeds from the offering are anticipated to be approximately $1.5 million before deducting placement agent fees and estimated offering expenses.

What are the intended uses of the net proceeds from the offering?

SINTX Technologies, Inc. plans to utilize the net proceeds, if any, for working capital and general corporate purposes.

Who is acting as the sole placement agent for the offering?

Maxim Group is acting as the sole placement agent in connection with this offering.

Sintx Technologies, Inc.


SINT Rankings

SINT Latest News

SINT Stock Data

Surgical and Medical Instrument Manufacturing
United States of America

About SINT

amedica is the only manufacturer of medical grade silicon nitride, an innovative biomaterial technology ideal for use in spinal fusion and across a variety of medical applications. our silicon nitride features a unique nanosurface texture that promotes bone growth and addresses clinical needs by providing excellent imaging capabilities and demonstrating antibacterial characteristics. our interbody fusion devices and pedicle screw systems are designed to benefit both the patient and the surgeon. with the only fda registered and iso 1345 certified silicon nitride medical device manufacturing facility in the world and a strong sales and distribution organization, we are committed to providing innovative healthcare solutions that improve patient quality of life.